| AASLD

Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

Read more about Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

Roger W. Chapman – 28 April 2014 – Watch a video presentation of this article

Systemic therapy for cholangiocarcinoma

Read more about Systemic therapy for cholangiocarcinoma

Saeed Sadeghi, Richard S. Finn – 28 April 2014 – Watch a video presentation of this article

Primary biliary cirrhosis: Family, genes, and bugs

Read more about Primary biliary cirrhosis: Family, genes, and bugs

George F. Mells – 28 April 2014 – Watch a video presentation of this article

Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation

Read more about Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation

Denise M. Harnois, Maria L. Yataco, Raouf E. Nakhleh – 28 April 2014 – Watch a video presentation of this article

Incorporation of primary patient‐derived glycoproteins into authentic infectious hepatitis C virus particles

Read more about Incorporation of primary patient‐derived glycoproteins into authentic infectious hepatitis C virus particles

Juliane Doerrbecker, Martina Friesland, Nina Riebesehl, Corinne Ginkel, Patrick Behrendt, Richard J.P. Brown, Sandra Ciesek, Heiner Wedemeyer, Christoph Sarrazin, Lars Kaderali, Thomas Pietschmann, Eike Steinmann – 27 April 2014 – The Japanese fulminant hepatitis‐1 (JFH1)‐based hepatitis C virus (HCV) infection system has permitted analysis of the complete viral replication cycle in vitro. However, lack of robust infection systems for primary, patient‐derived isolates limits systematic functional studies of viral intrahost variation and vaccine development.

IL‐20 and IL‐20R1 antibodies protect against liver fibrosis

Read more about IL‐20 and IL‐20R1 antibodies protect against liver fibrosis

Yi‐Shu Chiu, Chi‐Chen Wei, Yih‐Jyh Lin, Yu‐Hsiang Hsu, Ming‐Shi Chang – 25 April 2014 – Interleukin (IL)‐20 is a proinflammatory cytokine of the IL‐10 family and involved in rheumatoid arthritis, atherosclerosis, stroke, and osteoporosis. However, the pathophysiological roles of IL‐20 in liver injury have not been extensively studied. We explored the involvement of IL‐20 in liver injury and the therapeutic potential of IL‐20 antagonists for treating liver fibrosis.